CCS
AMPH icon

Crosspoint Capital Strategies’s Amphastar Pharmaceuticals AMPH Stock Holding History

Crosspoint Capital Strategies’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-596
Closed -$10K – 759
2015
Q2 		$10K Buy
+596
New +$9.29K ﹤0.01% 518

Other funds holding AMPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

Crosspoint Capital Strategies's AMPH Position: Q3 2015 in Review

Crosspoint Capital Strategies sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2015, closing a stake of 596 shares — an estimated $10K sold.

Crosspoint Capital Strategies first reported a position in AMPH in Q2 2015 and held it in 1 quarter. The position peaked at $10K in Q2 2015. 92 funds tracked by Wall St. Rank hold AMPH as of Q3 2015.

  • Crosspoint Capital Strategies reported no remaining Amphastar Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 596 Amphastar Pharmaceuticals shares in Q3 2015, an estimated $10K.
  • Crosspoint Capital Strategies first reported a position in Amphastar Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Amphastar Pharmaceuticals position peaked at $10K in Q2 2015.
  • 92 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2015, filed 25 Nov 2015.